Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 4

Effect of treatment on BCVA, CMT, and TMV values in vitrectomized eyes (n = 11).

	Mean ± SD	F value	value	Partial eta^2
BCVA (logMAR)
Baseline	0.70 ± 0.30	4.304	0.038	0.301
6^th month	0.56 ± 0.28
12^th month	0.51 ± 0.32
18^th month	0.41 ± 0.28
24^th month	0.44 ± 0.24
CMT (μm)
Baseline	330 ± 95	6.122	0.005	0.380
6^th month	300 ± 106
12^th month	272 ± 85
18^th month	211 ± 96
24^th month	221 ± 117
TMV (mm^3)
Baseline	9.35 ± 1.52	4.467	0.030	0.309
6^th month	8.62 ± 0.86
12^th month	8.52 ± 0.91
18^th month	8.29 ± 1.08
24^th month	8.25 ± 1.47

BCVA was measured with a standard Snellen chart and converted to the logarithm of the minimum angle of resolution (logMAR) units. BCVA indicates best-corrected visual acuity; CMT, central macular thickness; SD, standard deviation; TMV, total macular volume. Repeated measure ANOVA. None of the pairwise comparisons for BCVA, CMT, and TMV values were significant in the vitrectomized group.